Business
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
Key data includes results for intravenous administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Key data includes results for intravenous administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients\nDUBLIN, Nov. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts will be presented at the American Society of Hematology (ASH) Annual Meeting from December 10-13, 2022. Research findings to be presented include data from company-sponsored, investigator-sponsored and collaborative trials for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)/asparaginase, Vyxeos® (daunorubicin and cytarabine), also known as JZP351, and Defitelio® (defibrotide sodium).\n\"We're excited about our continued progress in oncology, including the impact that Rylaze is having to provide patients with a much-needed, reliable therapeutic option for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. \"The data at ASH from across Rylaze, Vyxeos and Defitelio demonstrate our commitment to continued evaluation of our products to make a difference for patients living with rare forms of leukemia and following hematopoietic stem cell transplant.\"\nHighlights from Jazz and its investigational sponsors at the congress include:\nA poster featuring results from Part B of a Phase 2/3 trial conducted with the Children's Oncology Group, evaluating the efficacy, safety, and population pharmacokinetic modeling of Rylaze administered intravenously (IV) in patients living with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). Results demonstrate that IV administration of Rylaze at 25 mg/m2 every 48 hours is feasible and efficacious with a safety profile consistent with other asparaginases.1A poster sharing a subgroup analysis from Arm B of the V-FAST Master Trial, evaluating outcomes of Vyxeos and midostaurin treatment in adults with newly diagnosed acute myeloid leukemia (de novo and secondary) with FLT3 mutation. Preliminary results suggest the combination of Vyxeos + MID is feasible with a manageable safety profile and promising remission rates in adults with newly diagnosed, FLT3-mutated AML.2A poster from a pooled analysis of two registry studies (DEFIFrance a...